Latest News

STAT Plus: Blackstone Group invests up to $2 billion in Alnylam, a big bet on the Cambridge biotech

The private equity firm Blackstone Group is investing up to $2 billion in Alnylam Pharmaceuticals, a big bet on the Cambridge biotech’s approach to developing drugs for genetic diseases and disorders that need better treatments.

The deal, which was announced Monday, is anchored by Blackstone’s purchase of half the royalties owed to Alnylam on global sales of inclisiran, an experimental RNA interference drug for the treatment of high cholesterol.

Continue to STAT Plus to read the full story…

Source link

Related posts

#MinorityMH Twitter Chat


New study estimates the caregiving costs for families


DHSC commits to AMR fight


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World